240 related articles for article (PubMed ID: 25633983)
21. Second-wave IFN-based triple therapy for HCV genotype 1 infection: simeprevir, faldaprevir and sofosbuvir.
Asselah T; Marcellin P
Liver Int; 2014 Feb; 34 Suppl 1():60-8. PubMed ID: 24373080
[TBL] [Abstract][Full Text] [Related]
22. [Biochemical and pharmacological features of telaprevir].
Andrade RJ; García-Samaniego J
Enferm Infecc Microbiol Clin; 2013 Jul; 31 Suppl 3():2-6. PubMed ID: 24063896
[TBL] [Abstract][Full Text] [Related]
23. Telaprevir for chronic hepatitis C virus infection.
Jesudian AB; Jacobson IM
Clin Liver Dis; 2013 Feb; 17(1):47-62. PubMed ID: 23177282
[TBL] [Abstract][Full Text] [Related]
24. [Hungarian consensus guideline for the diagnosis and treatment of B, C, and D viral hepatitis].
Makara M; Horváth G; Gervain J; Pár A; Szalay F; Telegdy L; Tornai I; Ujhelyi E; Hunyady B
Orv Hetil; 2012 Mar; 153(10):375-94. PubMed ID: 22370225
[TBL] [Abstract][Full Text] [Related]
25. Interferon-free antiviral combination therapies without nucleosidic polymerase inhibitors.
Welzel TM; Dultz G; Zeuzem S
J Hepatol; 2014 Nov; 61(1 Suppl):S98-S107. PubMed ID: 25443350
[TBL] [Abstract][Full Text] [Related]
26. HCVerso3: An Open-Label, Phase IIb Study of Faldaprevir and Deleobuvir with Ribavirin in Hepatitis C Virus Genotype-1b-Infected Patients with Cirrhosis and Moderate Hepatic Impairment.
Sarrazin C; Manns M; Calleja JL; Garcia-Samaniego J; Forns X; Kaste R; Bai X; Wu J; Stern JO
PLoS One; 2016; 11(12):e0168544. PubMed ID: 28030579
[TBL] [Abstract][Full Text] [Related]
27. [Treatment of hepatitis C: current status and perspectives].
Pol S; Corouge M
Rev Prat; 2014 May; 64(5):605-12. PubMed ID: 24923038
[TBL] [Abstract][Full Text] [Related]
28. Importance of HCV genotype 1 subtypes for drug resistance and response to therapy.
Wyles DL; Gutierrez JA
J Viral Hepat; 2014 Apr; 21(4):229-40. PubMed ID: 24597691
[TBL] [Abstract][Full Text] [Related]
29. Protease inhibitors: silver bullets for chronic hepatitis C infection?
Alkhouri N; Zein NN
Cleve Clin J Med; 2012 Mar; 79(3):213-22. PubMed ID: 22383557
[TBL] [Abstract][Full Text] [Related]
30. Optimal treatment with telaprevir for chronic HCV infection.
Jesudian AB; Jacobson IM
Liver Int; 2013 Feb; 33 Suppl 1():3-13. PubMed ID: 23286840
[TBL] [Abstract][Full Text] [Related]
31. [Hepatitis C: diagnosis, anti-viral therapy, after-care. Hungarian consensus guideline].
Hunyady B; Gerlei Z; Gervain J; Horváth G; Lengyel G; Pár A; Rókusz L; Szalay F; Telegdy L; Tornai I; Werling K; Makara M
Orv Hetil; 2015 Mar; 156(9):343-51. PubMed ID: 25702254
[TBL] [Abstract][Full Text] [Related]
32. Emerging therapies for hepatitis C.
Kim DY; Ahn SH; Han KH
Gut Liver; 2014 Sep; 8(5):471-9. PubMed ID: 25228970
[TBL] [Abstract][Full Text] [Related]
33. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-α and the protease inhibitors boceprevir or telaprevir.
Hofmann WP; Chung TL; Osbahr C; Susser S; Karey U; Mihm U; Welsch C; Lötsch J; Sarrazin C; Zeuzem S; Herrmann E
Antivir Ther; 2011; 16(5):695-704. PubMed ID: 21817191
[TBL] [Abstract][Full Text] [Related]
34. Interferon-free treatment of chronic hepatitis C with faldaprevir, deleobuvir and ribavirin: SOUND-C3, a Phase 2b study.
Zeuzem S; Dufour JF; Buti M; Soriano V; Buynak RJ; Mantry P; Taunk J; Stern JO; Vinisko R; Gallivan JP; Böcher W; Mensa FJ;
Liver Int; 2015 Feb; 35(2):417-21. PubMed ID: 25263751
[TBL] [Abstract][Full Text] [Related]
35. Impact of HCV protease-inhibitor-based triple therapy for chronic HCV genotype 1 infection.
Ferenci P; Reddy KR
Antivir Ther; 2011; 16(8):1187-201. PubMed ID: 22155901
[TBL] [Abstract][Full Text] [Related]
36. [Triple therapy in cirrhotic patients and those with advanced fibrosis: relevant aspects in clinical practice].
Albillos A; Luis Calleja J; Molina E; Planas R; Romero-Gómez M; Turnes J; Hernández-Guerra M
Gastroenterol Hepatol; 2014 Jul; 37 Suppl 1():13-22. PubMed ID: 25907434
[TBL] [Abstract][Full Text] [Related]
37. Simeprevir and sofosbuvir for treatment of chronic hepatitis C infection.
Childs-Kean LM; Hand EO
Clin Ther; 2015 Feb; 37(2):243-67. PubMed ID: 25601269
[TBL] [Abstract][Full Text] [Related]
38. Response-guided therapy in patients with genotype 1 hepatitis C virus: current status and future prospects.
Lawitz EJ; Membreno FE
J Gastroenterol Hepatol; 2014 Aug; 29(8):1574-81. PubMed ID: 24852401
[TBL] [Abstract][Full Text] [Related]
39. The role of triple therapy in HCV genotype 1-experienced patients.
Fried MW
Liver Int; 2011 Jan; 31 Suppl 1():58-61. PubMed ID: 21205139
[TBL] [Abstract][Full Text] [Related]
40. Triple therapy with first-generation protease inhibitors for patients with genotype 1 chronic hepatitis C: recommendations of the Italian association for the study of the liver (AISF).
; Coco B; Caraceni P; Aghemo A; Bitetto D; Bruno R; Ciancio A; Marzioni M; Petta S; Rendina M; Valenti L;
Dig Liver Dis; 2014 Jan; 46(1):18-24. PubMed ID: 24119482
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
